Separation method of compound with pancreatic lipase inhibitory activity in Tibetan medicine Sibiraea angustata and application of compound in preparation of weight-losing and lipid-lowering medicine
Patent Information
- Application Number
- CN202411484231.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-23
- Publication Date
- 2025-01-14
AI Technical Summary
Existing weight loss drugs such as orlistat have liver damage and adverse gastrointestinal side effects. The method of screening pancreatic lipase inhibitors from natural products is complex and time-consuming, making it difficult to effectively screen out significant weight loss and lipid-lowering effects. Element.
Affinity ultrafiltration-high performance liquid chromatography-quadrupole time-of-flight mass spectrometry technology was used to screen a variety of pancreatic lipase inhibitors from Liucha, combined with molecular docking technology and macroporous resin preparation chromatography method, and directional separation was strong Flavonoids with binding ability such as quercetin 3,4'-diglucoside and schizonepetin were verified for their pancreatic lipase inhibitory activity.
A variety of novel pancreatic lipase inhibitors were screened, especially quercetin 3,4'-diglucoside and schizonepetin, which had strong pancreatic lipase inhibitory activity, providing a new direction for the development of weight loss and lipid-lowering drugs, and through High performance liquid chromatography detection achieved high purity preparation of the target compound.
Smart Images
Figure CN119302974A_ABST